Company Analysis
Sign in

Minerva Neurosciences, Inc (NERV)

Nasdaq: NERV · Pharmaceutical Preparations · Burlington, MA · filing with the SEC since 2014
Full chart Alerts Compare
Grade6.0
◀ Past 6.3● Present 5.1▶ Future 6.7
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

10 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Minerva Neurosciences, Inc’s names, not what it holds today.

Patents granted
10
10 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 2 in 2024 and 1 in 2023
Applications published
32
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'14'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Minerva Neurosciences, Inc. its own name
named as the applicant on its applications, in US
0 granted
30 published
Minerva Neurosciences, Inc. its own name
US, as the owner printed on each patent
10 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 30, 202412,048,768Gastro-resistant controlled release oral dosage formsPharmaceuticalsMinerva Neurosciences, Inc.
Jun 11, 202412,006,300Sigma ligand compounds and uses thereofOrganic fine chemistryMinerva Neurosciences, Inc.
Sep 26, 202311,766,430Methods of using a phenoxypropylamine compound to treat painPharmaceuticalsMinerva Neurosciences, Inc.
Oct 11, 202211,464,744Gastro-resistant controlled release oral dosage formsPharmaceuticalsMinerva Neurosciences, Inc.
Aug 10, 202111,083,723Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotectionPharmaceuticalsMinerva Neurosciences, Inc.
Oct 13, 202010,799,493Compositions and methods for treating schizophreniaPharmaceuticalsMinerva Neurosciences, Inc.
Apr 16, 201910,258,614Compositions and methods for treating schizophreniaPharmaceuticalsMinerva Neurosciences, Inc.
Aug 15, 20179,732,059Methods of use of cyclic amide derivatives to treat schizophreniaDigital communicationMinerva Neurosciences, Inc.
Aug 15, 20179,730,920Compositions and methods for treating schizophreniaPharmaceuticalsMinerva Neurosciences, Inc.
Oct 4, 20169,458,130Compositions and methods for treating schizophreniaPharmaceuticalsMinerva Neurosciences, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 24, 20252025/0235443USE OF ROLUPERIDONE TO TREAT NEGATIVE SYMPTOMS AND DISORDERS, INCREASE NEUROPLASTICITY, AND PROMOTE NEUROPROTECTIONPharmaceuticalsMinerva Neurosciences, Inc.
Jul 17, 20252025/0228838METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SIGMA RECEPTOR MEDIATED DISORDERSPharmaceuticalsMinerva Neurosciences, Inc.
Jul 17, 20252025/0228837(2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERSPharmaceuticalsMinerva Neurosciences, Inc.
Jun 19, 20252025/0195494COMPOSITIONS AND METHODS FOR TREATING SCHIZOPHRENIAPharmaceuticalsMinerva Neurosciences, Inc.
Jun 5, 20252025/0179044METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIADigital communicationMinerva Neurosciences, Inc.
Apr 3, 20252025/0109127METHODS OF USE OF PHENOXYPROPYLAMINE COMPOUNDS TO TREAT DEPRESSIONPharmaceuticalsMinerva Neurosciences, Inc.
Jan 9, 20252025/0009665GASTRO-RESISTANT CONTROLLED RELEASE ORAL DOSAGE FORMSPharmaceuticalsMinerva Neurosciences, Inc.
Nov 14, 20242024/0376068SIGMA LIGAND COMPOUNDS AND USES THEREOFOrganic fine chemistryMinerva Neurosciences, Inc.
Jan 18, 20242024/0016790METHODS OF USING A PHENOXYPROPYLAMINE COMPOUND TO TREAT PAINPharmaceuticalsMinerva Neurosciences, Inc.
Aug 17, 20232023/0255953USE OF ROLUPERIDONE IN PREVENTING RELAPSE IN SCHIZOPHRENIA PATIENTSPharmaceuticalsMinerva Neurosciences, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Organic fine chemistry 1 · Digital communication 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NERV · research, not advice